It is our pleasure to welcome you onto our website and present you CleveXel Pharma.
Created in 2013 as a spinoff from Cephalon Inc. (TEVA group), CleveXel Pharma is a pharmaceutical company specializing in innovative treatments for diseases of the central nervous system.
The Company is developing a portfolio of drug candidates, including two disruptive molecules for treating Parkinson’s disease. The most advanced of these, CVXL-0107, which is currently in phase IIa clinical trials, aims to improve the quality of life of Parkinson’s patients and treat motor impairments resulting from the reference treatment, L-Dopa.
The other drug candidate, CVXL-0069, focuses on the early treatment of motor and non-motor symptoms of Parkinson’s.
Thanks to our unique expertise in diseases of the central nervous system and our know-how in drug development, we have strong assets to bring these molecules with high potential to clinical proof of concept, a critical stage for creation of value. Our partnership policy and our ability to identify molecules of therapeutic potential at an early stage are another strength of our model.
We hope our website will provide you with quality information about our activity and we will be happy to explore them deeper with you during our exchanges.